Search clinical trials for: CS1003 Placebo Lenvatinib

Total 54130 results

Eisai Co., Ltd.

Completed

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Biliary Tract Cancer

Japan
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study (LEAP-007)

Non-small Cell Lung Cancer

China
Chang Gung Memorial Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence

Taiwan
Sun Yat-sen University

Not yet recruiting

A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma

Potentially Resectable Hepatocellular Carcinoma
Fudan University

Recruiting

PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC

Hepatocellular Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
RenJi Hospital

Unknown

Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation (RRHCCLT)

Liver Transplantation | Hepatocellular Carcinoma
Hoffmann-La Roche

Terminated

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

Influenza

United States
Fujian Medical University

Recruiting

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Overall Response Rate

China
Zhejiang Cancer Hospital

Recruiting

Lenvatinib Combined With Tislelizumab and TACE Applied as Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma With High-risk Recurrence Factors

Hepatocellular Carcinoma | Oxaliplatin | TACE | Lenvatinib | Tislelizumab | Pharmorubicin

China
Henan Cancer Hospital

Recruiting

Lenvatinib for Advanced Bone and Soft Tissue Sarcoma

Sexuality | Effectiveness

China
Fudan University

Recruiting

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma

China
National University Hospital, Singapore

Recruiting

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Adenocarcinomas | Recurrent Gynecological

Singapore
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
RenJi Hospital

Completed

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Hepatocellular Carcinoma | Molecular Targeted Therapy

China
Sun Yat-sen University

Recruiting

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

Liver Tumor

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Xinrui Zhu

Enrolling by invitation

The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable | Tyrosine Kinase Inhibitor | Transarterial Chemoembolization | Immune Checkpoint Blockade

China
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Carcinoma, Hepatocellular

United States, Australia, Canada, Chile, China, Colombia, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Spain, Taiwan, Thailand, Turkey, United Kingdom
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma

Hepatocellular Carcinoma Stage III
Shanghai Zhongshan Hospital
West China Hospital; Tongji Hospital; Anhui Provincial Hospital

Unknown

Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

Hepatocellular Carcinoma (HCC)

China
University of Jena

Completed

Effects of Soluble Phosphate in Humans

Healthy Volunteers

Germany
Peking University

Recruiting

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
CStone Pharmaceuticals

Completed

A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Lymphoma | Solid Tumor

China
Visirna Therapeutics HK Limited

Not yet recruiting

A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

Dyslipidemias | Hypertriglyceridemia | Familial Hypercholesterolemia
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors

China
Histogen
United States Department of Defense

Terminated

Human ECM Implanted Within Microfracture Interstices & the Cartilage Defect in the Knee to Regenerate Hyaline Cartilage (hECM;HST003)

Cartilage Damage | Articular Cartilage Disorder of Knee | Microfractures

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

China
Peking Union Medical College Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Advanced Biliary Tract Cancer

China
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection

Tuberculosis

United States
QIAGEN Gaithersburg, Inc

Completed

Evaluation of the QuantiFERON-TB Test.

Tuberculosis

United States
Maruho Co., Ltd.

Completed

First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts

Cutaneous Warts

Netherlands
Sun Yat-sen University

Recruiting

TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

Hepatocellular Carcinoma

China
Fudan University

Recruiting

Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...

Not yet recruiting

Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma (PULSAR)

Classic Kaposi Sarcoma | Kaposi Sarcoma | Refractory Kaposi Sarcoma
Sun Yat-sen University

Recruiting

PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial (PLATIC)

Hepatocellular Carcinoma

China
Peking Union Medical College Hospital

Recruiting

Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Biliary Tract Neoplasms | Immunotherapy

China
University College, London
Merck Sharp & Dohme LLC

Recruiting

Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (PRIMER-1)

Hepatocellular Carcinoma

United Kingdom
Chen Xiaoping

Not yet recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

HCC
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Tianjin Medical University Second Hospital

Recruiting

Pembrolizumab Plus Lenvatinib in Stage III-IV RCC

Advanced Kidney Cancer

China
BeiGene

Active, not recruiting

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors

Advanced Solid Tumor

China
Shanghai Zhongshan Hospital

Enrolling by invitation

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Enrolling by invitation

Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

Hepatocellular Carcinoma

China
Eisai Co., Ltd.
Merck Sharp & Dohme LLC

Completed

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Solid Tumors

Japan
Jinling Hospital, China

Recruiting

Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC

Neoplasms | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Carcinoma | Antineoplastic Agents | Male Urogenital Diseases | Female Urogenital Diseases | Immune Checkpoint Inhibitors | Urogenital Diseases

China
M.D. Anderson Cancer Center
STRATEGIC ALLIANCE: Merck

Recruiting

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Adenocarcinoma | Tumor

United States
CStone Pharmaceuticals

Completed

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Solid Tumor, Adult

Australia
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Hepatocellular Carcinoma Non-resectable

China

3

Subscribe